Here's why the Creso Pharma (ASX:CPH) share price is falling 7%

The Creso Pharma Ltd (ASX: CPH) share price has falling 6.5% after a heavily oversubscribed placement to advance its psychedelics trials

| More on:
white arrow pointing down

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Creso Pharma Ltd (ASX: CPH) shares are falling today after the company received firm commitments to raise A$18 million. At the time of writing, the Creso share price has slumped 6.52% to 21.5 cents.

The funds raised will be deployed to undertake psychedelic clinical trials upon the completion of the company's Halucenex acquisition. Halucenex is a life sciences company focused on researching novel psychedelic compounds and developing and licensing products for the emerging global psychedelic medicines market. 

Creso share price falls on capital raise 

The Creso share price is on the slide today after the company advised it has secured firm commitments from institutional, professional and sophisticated investors to raise up to A$18 million. The funds will be raised via the issue of approximately 94.7 million new shares at an issue price of 19 cents per share. 

The company notes that the placement was heavily oversubscribed and strongly supported by a range of local and international groups including leading Australian businessman John Langley Hancock, S3 Consortium Holdings Pty Ltd and independent global fund manager L1 Global Master Opportunities Fund, among others. 

Funds to advance clinical trials and nutraceutical offerings 

Creso Pharma has recently focused its attention on its "transformational" psychedelics acquisition, Halucenex. Its phase II and phase III clinical trials will explore the efficacy of psychedelic molecules on a range of mental health conditions, such as depression and post-traumatic stress disorder, and open up another potentially lucrative vertical. 

The company will also deploy funds to expand its current nutraceutical offerings via its wholly-owned Canadian subsidiary, Mernova Medicinal Inc. On 19 March, Mernova received three purchase orders valued at C$177,122.40 (A$183,019.551). These included the company's first purchase order for its pre-roll joint range, sold under the Ritual Sticks brand. 

Non-executive chair Adam Blumenthal was pleased with the strong interest in the placement and believes it will position Creso to explore greater opportunities in the near-term. He said:

The Placement was very well bid and leaves Creso Pharma well funded to progress a number of near term revenue generating initiatives. Key short-term focus will include finalising the acquisition of Halucenex and undertaking clinical trials. Importantly, the acquisition provides the Company with access to another lucrative vertical and potential revenue stream. We will also be ramping up our nutraceutical division and preparing for the anticipated legalisation of cannabis in the US through our Canadian operations.

The Creso share price has increased by more than 250% over the past 12 months.

Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »